Concurrent Weekly Cisplatin Versus Triweekly Cisplatin with Radiotherapy in the Treatment of Cervical Cancer: A Meta-analysis Result

  • Hu, Yan (Department of Oncology, The First People's Hospital of Jingzhou) ;
  • Cai, Zhi-Qiang (Department of Oncology, The First People's Hospital of Jingzhou) ;
  • Su, Xiao-Yan (Department of Oncology, The First People's Hospital of Jingzhou)
  • Published : 2012.09.30


Aims: To evaluate the adverse effect and survival outcome of weekly and triweekly cisplatin with radiotherapy in treatment of cervical cancer. Methods: After an extensive literature search between 1995-2011, we analyzed 7 studies to compare weekly cisplatin and triweekly cisplatin combined radiotherapy. Results: Our analysis established that weekly cisplatin has a lower risk of hematologic toxicity than triweekly cisplatin with concurrent radiotherapy in the treatment of cervical cancer. However, there were no differences in progression free survival and overall survival between weekly cisplatin and triweekly cisplatin (p>0.05). Conclusions: Weekly cisplatin combined with concurrent radiation has lower risk in hematologic toxicity than triweekly cisplatin, but does not improve survival. Triweekly cisplatin treatment has longer intervals and is therefore more convenient. Clinicians and patients can choose either weekly cisplatin or triweekly cisplatin combined radiotherapy for cervical cancer.


  1. Barnholtz-Sloan J, Patel N, Rollison D, et al (2009). Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control, 20, 1129-38.
  2. Eifel PJ, Winter K, Morris M, et al (2004). Pelvic irradiation with concurrent chemotherapy versus pelvic and paraaortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol, 22, 872-80.
  3. Harrison L, Blackwell K (2004). Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy. Oncologist, 9, 31-40.
  4. Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB (2000). The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 78, 137-42.
  5. Idei T, Sakamoto H, Nalajima Y, et al (2003). Concurrent weekly nedaplatin-based radiotherapy for high risk recurrent and advanced cervical cancer. Gan To Kagaku Ryoho, 30, 505-9.
  6. Katanyoo K, Tangjitgamol S, Chongthanakorn M, et al (2011). Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. Gynecol Oncol, 123, 571-6.
  7. Kim YS, Shin SS, Choi EK, et al (2005). A preliminary result of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer. Cancer Res Treat, 37, 37-43.
  8. Kim YS, Shin SS, Nam JH, et al (2008). Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol, 108, 195-200.
  9. Klopp AH, Eifel PJ (2011). Chemoradiotherapy for cervical cancer in 2010. Curr Oncol Rep, 13, 77-85.
  10. Lee HN, Lee KH, Lee DW, et al (2011).Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer. Int J Gynecol Cancer, 21, 128-36.
  11. Niibe Y, Hayakawa K, Tsunoda S, et al (2007). Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma:Kitasto Gynecologic Radiation Oncology Group (KGROG 0501). Jpn J Clin Oncol, 37, 70-2.
  12. Rose PG, Ali S, Watkins E, et al (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin,cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a gynecologic oncology group study. J Clin Oncol, 25, 2804-10.
  13. Rose PG, Bundy BN, Watkins EB, et al (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally cervical cancer. N Engl J Med, 340, 1144-53.
  14. Ryu SY, Lee WM, Kim K, et al (2011). Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys, 81, e577-81.
  15. Thomas GM (1999). Improved treatment for cervical cancerconcurrent chemotherapy and radiotherapy. N Engl J Med, 340, 1198-200.
  16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 7, 16.
  17. Torres MA, Jhingran A, Thames HD Jr, et al (2008). Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys, 70, 118-25.
  18. Winter WE 3rd, Maxwell GL, Tian C, et al (2004). Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group study. Gynecol Oncol, 94, 495-501.

Cited by

  1. Extended Field Radiotherapy With or Without Chemotherapy in Patients with Cervical Cancer and Positive Para-Aortic Lymph Nodes: a Single Institution Retrospective Review vol.16, pp.9, 2015,
  2. Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer vol.27, pp.2, 2017,
  3. triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution vol.90, pp.1076, 2017,
  4. Significant Effect of Acupressure in Elevating Blood Stem Cell Factor During Chemotherapy in Patients With Gynecologic Cancer pp.1682-3141, 2017,
  5. Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer vol.97, pp.30, 2018,